Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Int J Cardiol ; 321: 24-29, 2020 Dec 15.
Article in English | MEDLINE | ID: mdl-32800911

ABSTRACT

OBJECTIVE: We aimed to assess the use of enhanced stent visualisation (ESV) on outcomes, after PCI with overlapping stents, specifically using CLEARstent technology. BACKGROUND: Stent underexpansion and overlap are both significant risk factors for restenosis and stent thrombosis. Enhanced stent visualisation (e.g. CLEARstent) systems could provide important data to reduce under-expansion and stent overlap. METHODS: This was a cohort study based on this institution's percutaneous coronary intervention (PCI) registry. A total of 2614 patients who had PCI for stable angina or acute coronary syndromes (ACS, excluding cardiogenic shock) with overlapping 2nd generation drug eluting stents (DES) in the same vessel between May 2015 and January 2018 were included in the analysis. Patients were divided into ESV (n = 1354) and no ESV guided intervention (n = 1260). The primary end-point was major adverse cardiovascular events (MACE: target vessel revascularisation, target vessel myocardial infarction and all-cause mortality) recorded at a median follow up of 2.4 years. RESULTS: Groups were comparable for patient characteristics (age, diabetes mellitus, ACS presentation). A significant difference in MACE was observed between patients who underwent ESV-guided PCI (9.5%) compared with patients who underwent Standard PCI (14.4%, p = .018). This difference was mainly driven by reduced rates of target vessel revascularisation and recurrent myocardial infarction. Overall this difference persisted after multivariate Cox analysis (HR 0.86, 95% CI: 0.73-0.98) and propensity matching (HR = 0.88, 95% CI: 0.69-0.99). CONCLUSION: We suggest that routine clinical use of ESV technology during PCI can be useful, and is associated with better medium-term angiographic and clinical outcomes. Further study is required to build on this promising signal.


Subject(s)
Percutaneous Coronary Intervention , Angiography , Cohort Studies , Coronary Angiography , Humans , Percutaneous Coronary Intervention/adverse effects , Risk Factors , Stents , Treatment Outcome
2.
Minerva Cardioangiol ; 61(2): 99-123, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23492595

ABSTRACT

Drug-eluting stents (DES) have transformed interventional cardiology over the past decade. Whilst their efficacy has rarely been called into question, there have been concerns over the safety of the early devices, which has prompted the development of new coronary stents. Many of these new devices have entered clinical practice, however questions remain as to whether they offer the improvements in clinical outcomes that were originally anticipated. In addition, there is a debate whether the reported high efficacy of these devices enables percutaneous coronary intervention (PCI) to be performed in patient and lesion sub-groups previous entirely the domain of the cardiac surgeon. This review paper addresses these outstanding questions.


Subject(s)
Drug-Eluting Stents , Percutaneous Coronary Intervention/instrumentation , Biocompatible Materials , Clinical Trials as Topic , Combined Modality Therapy , Comorbidity , Coronary Restenosis/prevention & control , Coronary Stenosis/surgery , Coronary Thrombosis/drug therapy , Coronary Thrombosis/surgery , Diabetes Complications , Disease-Free Survival , Drug-Eluting Stents/adverse effects , Drug-Eluting Stents/statistics & numerical data , Drug-Eluting Stents/trends , Humans , Meta-Analysis as Topic , Multicenter Studies as Topic , Myocardial Infarction/epidemiology , Myocardial Infarction/prevention & control , Paclitaxel/administration & dosage , Paclitaxel/therapeutic use , Percutaneous Coronary Intervention/methods , Polymers/chemistry , Postoperative Complications/epidemiology , Sirolimus/administration & dosage , Sirolimus/therapeutic use , Thrombolytic Therapy , Treatment Outcome
3.
Article in English | MEDLINE | ID: mdl-23366469

ABSTRACT

The aim of this study is to describe a new method for three-dimensional (3D) reconstruction of coronary arteries using Frequency Domain Optical Coherence Tomography (FD-OCT) images. The rationale is to fuse the information about the curvature of the artery, derived from biplane angiographies, with the information regarding the lumen wall, which is produced from the FD-OCT examination. The method is based on a three step approach. In the first step the lumen borders in FD-OCT images are detected. In the second step a 3D curve is produced using the center line of the vessel from the two biplane projections. Finally in the third step the detected lumen borders are placed perpendicularly onto the path based on the centroid of each lumen border. The result is a 3D reconstructed artery produced by all the lumen borders of the FD-OCT pullback representing the 3D arterial geometry of the vessel.


Subject(s)
Coronary Angiography/methods , Coronary Vessels/physiology , Tomography, Optical Coherence/methods , Algorithms , Humans , Image Processing, Computer-Assisted , Imaging, Three-Dimensional
4.
Angiology ; 60(6): 757-62, 2009.
Article in English | MEDLINE | ID: mdl-19114409

ABSTRACT

INTRODUCTION: The aim of our study was to investigate whether collagen degradation is altered in participants with masked hypertension and whether this alteration could be related to disturbances in the matrix metalloproteinases plasma concentration and to compare the findings with those participants with normal blood pressure levels matched for age, sex, and body mass index. METHODS: Twenty-four (11 men, 13 women) participants with masked hypertension [mean age 46 +/- 7 years and body mass index 25.9 +/- 2.1 kg/m(2) (group A)] and 106 healthy normotensives (49 men, 57 women) with normal blood pressure [mean age 44 +/- 6 years and body mass index 25.5 +/- 2.4 kg/m(2) (group B)]. RESULTS: The plasma levels of matrix metalloproteinase-9 were significantly higher, while the levels of tissue inhibitors of metalloproteinases-1 and -4 were significantly lower in group A compared with group B (matrix metalloproteinase-9: 569 +/- 135 vs. 282 +/- 117 ng/mL, TIMP-1: 169 +/- 42 vs. 230 +/- 37 ng/mL, P < .01, and TIMP-4: 2.1 +/- 1.3 vs. 4.2 +/- 1.98 ng/mL, P < .04, respectively). CONCLUSIONS: Patients with masked hypertension had significantly increased matrix metalloproteinase-9 plasma levels and significantly decreased plasma levels of tissue inhibitors of metalloproteinases-1 and -4 compared with participants with normal blood pressure. These findings need further investigation.


Subject(s)
Blood Pressure/physiology , Hypertension/enzymology , Metalloproteases/blood , Adult , Biomarkers/blood , Blood Pressure Monitoring, Ambulatory , Body Mass Index , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Hypertension/physiopathology , Male , Middle Aged , Severity of Illness Index
7.
Br J Radiol ; 78(926): 122-9, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15681323

ABSTRACT

The aim of this work was to evaluate a new semi-automated intravascular ultrasound (IVUS) border detection method. The method was used to identify the lumen and the external elastic membrane or the borders of stents in 80 IVUS images, randomly selected from 10 consecutive human coronary arteries. These semi-automated results were compared with observations of two experts. Several indices in each case were obtained in order fully to evaluate the method. The time required for identification of the borders was also recorded. The interobserver variability of the method ranged from 1.21% to 5.61%, the correlation coefficient from 0.98 to 0.99, the slope was close to unity (0.94-1.03), the y intercept close to zero and the Williams index value was close to unity (range 0.67-0.91). The time (mean+/-SD) required for the method to identify the borders of the different vessel layers for the whole IVUS sequence was 5.2+/-0.2 min. The results demonstrate that the method is reliable and capable of identifying rapidly and accurately the different vessel layers depicted in IVUS images.


Subject(s)
Coronary Disease/diagnostic imaging , Coronary Vessels/diagnostic imaging , Endosonography/methods , Stents , Aged , Automation , Coronary Disease/pathology , Coronary Vessels/pathology , Female , Humans , Male , Middle Aged , Observer Variation , Sensitivity and Specificity
8.
Am J Hematol ; 62(4): 201-7, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10589074

ABSTRACT

Disturbances of acid-base balance and electrolyte abnormalities are commonly seen in patients with acute leukemia. Our study aimed at illuminating the probable pathogenetic mechanisms responsible for these disturbances in patients with acute leukemia admitted to our hospital. We studied 66 patients (24 men and 44 women) aged between 17 and 87 years old on their admission and prior to any therapeutic intervention. Patients with diabetes mellitus, acute or chronic renal failure, hepatic failure, patients receiving drugs that influence acid-base status and electrolyte parameters during the last month, such as corticosteroids, cisplatin, diuretics, antacids, aminoglycosides, amphotericin, penicillin, and K(+), PO(4)(3-), or Mg(2+) supplements were excluded. Forty-one patients had at least one acid-base or electrolyte disturbance. There were no significant differences in the incidence of acid-base balance and electrolyte abnormalities between patients with acute myeloid leukemia (AML) and patients with acute lymphoblastic leukemia (ALL). The most frequent electrolyte abnormality was hypokalemia, observed in 41 patients (63%), namely in 34 patients with AML, and 7 with ALL; the main underlying pathophysiologic mechanism was inappropriate kaliuresis. Furthermore, hypokalemic patients more frequently experienced concurrent electrolyte disturbances (i.e., hyponatremia, hypocalcemia, hypophosphatemia, and hypomagnesemia), as well as various acid-base abnormalities compared to normokalemic patients. Hypokalemia in patients with acute leukemia may serve as an indicator of multiple concurrent, interrelated electrolyte disturbances, especially in patients with AML.


Subject(s)
Acid-Base Imbalance/etiology , Electrolytes/blood , Leukemia, Myeloid, Acute/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Acidosis/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Alkalosis/etiology , Female , Humans , Hydrogen-Ion Concentration , Hypocalcemia/etiology , Hypokalemia/etiology , Hyponatremia/etiology , Hypophosphatemia/etiology , Hypoxia/etiology , Magnesium Deficiency/etiology , Male , Middle Aged
10.
Med Pediatr Oncol ; 18(4): 333-5, 1990.
Article in English | MEDLINE | ID: mdl-2355894

ABSTRACT

A case of angiofollicular lymph node hyperplasia of plasma cell type in a 60-year-old woman is reported. The patient presented with lymphadenopathy, splenomegaly, and fever. She responded dramatically to chlorambucil and corticosteroids and has remained free of disease for the last 30 months. The authors review and discuss the systemic cytotoxic treatment of this clinicopathologic entity.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Castleman Disease/drug therapy , Castleman Disease/diagnosis , Chlorambucil/administration & dosage , Female , Humans , Middle Aged , Prednisone/administration & dosage , Remission Induction
11.
Angiology ; 32(4): 249-56, 1981 Apr.
Article in English | MEDLINE | ID: mdl-7224235

ABSTRACT

An accidental clinical observation triggered this investigation into the possible beneficial effects of isoxsuprine in the treatment of painful sickle cell crisis. Twenty-four patients were studied with a total of 34 episodes of painful crisis. As they had all been previously treated by us we knew the duration of their crisis under conventional treatment, so that the two regimens with and without isoxsuprine could be compared. Isoxsuprine was administered in 3 successive steps: (1) as an IM injection (5-10 mg), (2) as a rapid IV infusion (1 mg/minute), and (3) as a slow, continuous IV infusion, (0.1-0.3 mg/minute). The results from this study suggest that isoxsuprine exerts in fact a remarkable action in sickle cell crisis by bringing about prompt relief in approximately 80% of the cases within 5 hours, and in 40% of the cases within 2 hours. There were only 2 cases of absolute failure. The hospitalization time was remarkably reduced and the use of narcotics was minimized. Side effects (tachycardia, palpitations, somnolence) have been observed mainly in cases where relatively high doses of isoxsuprine had to be administered IV.


Subject(s)
Anemia, Sickle Cell/drug therapy , Isoxsuprine/therapeutic use , Female , Humans , Infusions, Parenteral , Injections, Intramuscular , Injections, Intravenous , Isoxsuprine/administration & dosage , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...